Oxidative stress in chronic hepatitis C: A preliminary study on the protective effects of antioxidant flavonoids

Hepato-Gastroenterology

Volumn 52, Issue 62, 2005, Pages 530-536

  Emerit, Ingrid ^a,e   Huang, Chung Yang ^b   Serejo, Fatima ^c   Filipe, Paulo ^c,d   Fernandes, Afonso ^c   Costa, Adilia ^c   Freitas, Joao ^c   Baptista, Amelia ^c   Carneiro De Moura, Miguel ^c  

^a SORBONNE UNIVERSITÉ   (France)

^b LANZHOU UNIVERSITY   (China)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

Antioxidants; Flavonoids; Hepatitis C; Interferon; Oxidative stress; Ribavirin; Sustained response

Indexed keywords

AMINOTRANSFERASE; ANTIOXIDANT; ANTIOXIDANT BIOFACTOR; FLAVONOID; HERBACEOUS AGENT; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SUPEROXIDE; UNCLASSIFIED DRUG;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFENSE MECHANISM; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEPATITIS C; HUMAN; LIVER PROTECTION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTIOXIDANTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CYTOPROTECTION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLAVONOIDS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; OXIDATIVE STRESS; PHENOLS; PILOT PROJECTS; PLANT EXTRACTS; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRANSAMINASES; TREATMENT OUTCOME;

EID: 16344394565     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Marcellin P, Boyer N: Chronic viral hepatitis. Best Pract Res Clin Gastroenterol 2003; 17:259-275.
2. Higueras V, Raya A, Rodrigo JM, Serra MA, Roma J, Romero FJ: Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radic Biol Med 1994; 16:131-133.
3. Romero MJ, Bosch-Morell F, Romero B, Rodrigo JM, Serra MA, Romero FJ: Serum malondialdehye. Possible use for the clinical management of chronic hepatitis C patients. Free Radic Biol Med 1998; 25:993-999.
4. Paradis V, Mathurin P, Kollinger M, Imbert-Bismuth F, Charlotte F, Piton A, Opolon P, Holstege A, Poynard T, Bedossa P: In situ detection of lipid peroxidation in chronic hepatitis C. Correlation with pathological features. J Clin Pathol 1997; 50:401-406.
5. De Maria N, Colantoni A, Fagiuoli, Liu GJ, Rogers BK, Farinati F, Van Thiel TH, Floyd RA: Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996; 21:291-295.
6. Shimoda R, Nagashima M, Sakamoto M, Yamaguchi N, Hirohashi S, Yokota J, Kasai H: Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994; 54:3171-3172.
7. Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C: DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 2001; 34:587-592.
8. Mutlu-Türkoglu U, Ademoglu E, Türkoglu S, Badur S, Uysal M, Toker G: The effects of interferon alpha on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis C. Res Commun Mol Pathol Pharmacol 1997; 96:357-361.
9. Swietek K, Juszczyk J: Reduced glutathione concentration in erythrocytes of patients with chronic viral hepatitis. J Viral Hepat 1997; 4:139-141.
10. Valgimigli L, Valgimigli M, Gaiani S, Pedulli GF, Bolondi L: Measurement of oxidative stress in human liver by EPR spin probe technique. Free Radic Res 2000; 33:167-178.
11. Chen M-F, Mo L-R, Lin R-C, Kuo J-Y, Chang K-K, Liao C, Lu F-J: Increase of resting superoxide anion in the whole blood of patients with decompensated liver cirrhosis. Free Radic Biol Med 1997; 23:672-679.
12. Serejo F, Filipe P, Emerit I, Freitas J, Fernandes A, Ramalho F, Carneiro de Moura M: Biomarkers of oxidative stress in patients with chronic hepatitis C. J Hepatol 1998; 28/S:105.
13. Emerit I, Serejo F, Filipe P, Alaoui-Youssefi A, Fernandes A, Costa A, Freitas J, Ramalho F, Baptista A, Carneiro de Moura M: Clastogenic factors as biomarkers of oxidative stress in chronic hepatitis C. Digestion 2000; 62:200-207.
14. Emerit I: Reactive oxygen species, chromosome mutation and cancer: possible role of clastogenic factors in carcinogenesis. Free Radic Biol Med 1994; 16:99-109.
15. Emerit I, Garban F, Vassy J, Filipe P, Freitas J: Superoxide-mediated clastogenesis and anticlastogenic effects of exogenous superoxide dismutase. Proc Natl Acad Sci USA 1996; 93:12799-12804.
16. Emerit I: Clastogenic factors as biomarkers of oxidative stress. Their usefulness for evaluation of the efficacy of antioxidant treatment. In: Özben T (Ed.). Free Radicals, Oxidative Stress and Antioxidants. New York: Plenum Press, 1998; pp. 375-384.
17. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia, N: N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: A pilot study. J Interferon Res 1993; 13:279-282.
18. Bernhard M.C, Junker E, Hettinger A, Lauterburg BH: Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon alpha with and without supplementation with N-acetyl cysteine. J Hepatol 1998; 28:751-755.
19. Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113:1069-1973.
20. Von Herbay A, Stahl W, Niederau C, Sies H: Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomised double-blind, placebo-controlled study. Free Radic Res 1997; 27:599-605.
21. Neri S, Terna D, Antoci S, Campanile E, D'Amico RA, Noto R: Association of alpha-interferon and acetyl cysteine in patients with chronic hepatitis C. Panminerva Med 2000; 42:187-192.
22. Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U: Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res 1999; 43:113-122.
23. Emerit I: Clastogenic factors: Detection and assay. Methods Enzymol 1990; 186:555-564.
24. Yagi K: Assay for serum lipid peroxide level and its clinical significance. In: Yagi K (Ed.). Lipid peroxidation. New York: Academic Press, 1988; pp. 223-242.
25. Hu M: Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233:380-385.
26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
27. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
28. Yuting C, Rongliang Z, Zhonghan J, Yong J: Flavonoids as superoxide scavengers and antioxidants. Free Radic Biol Med 1990; 9:19-21.
29. Mousavi Y, Adlercreutz H: Genistein is an effective stimulator of the hormone-binding globulin production in hepatocarcinoma cells in culture. Steroids 1993; 58:301-304.
30. Minamiyama Y, Yoshikawa T, Tanigawa T, Takahashi S, Naito Y, Ichikawa H, Kondo M: Antioxidative effects of a processed grain food. J Nutri Sci Vitaminol 1994; 40:467-477.
31. Emerit I, Oganesian N, Arutyunian R, Pogossian A, Sarkisian T, Cernjavski L, Levy A, Feingold J: Oxidative stress-related clastogenic factors in plasma from Chernobyl liquidators: protective effects of antioxidant plant phenols, vitamins and oligoelements. Mutat Res 1997; 377:139-246.
32. Minamiyama Y, Takemura S, Toyokuni S, Tanimoto Y, Sato E.F, Inoue M: A processed grain food inhibits hepatic injury in endotoxemic rats. J Nutri Sci Vitaminol 1998; 44:547-559.
33. Flora K, Hahn M, Rosen H, Brenner, K: Milk thistle (Silybum marinum) for the therapy of liver diseases. Am J Gastroenterol 1996; 93:139-143.
34. Mira L, Silva M, Manso CF: Scavenging of reactive oxygen species by silibinin hemisuccinate. Biochem Pharmacol 1994; 48:753-759.
35. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, Suzuki Y: The long-term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79:1494-1500.
36. Van Rossum TG, Vulto A, de Man RA, Brouwer JY, Schalm SW: Glycyrrhizin as a potential treatment for chronic hepatitis C. Alimentary Pharmacol Therapeutics 1998; 21:199-205.
37. Liu J, Xiao PG: Recent advances in the study of antioxidative effects of Chinese medicinal plants. Phytotherapy Res 1994; 8:445-451.
38. Cyong JC, Kim SM, Iijima KBL, Kobayashi T, Furuya M: Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chinese Med 2000; 28:351-360.
39. Cohen, MR: Herbal and complementary and alternative medicine therapies for liver disease. Clin Liver Dis 2001; 2:461-478.
40. Patrick L: Hepatitis C. Epidemiology and review of complementary/ alternative medicine treatments. Alternative Med Review 1999; 4:220-238.
41. Schuppan D, Jia JD, Brinkhaus B, Hahn EG: Herbal products for liver diseases: a therapeutic challenge for the new millennium. Hepatology 1999; 30:1099-1104.
42. Seef LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH: Complementary and alternative Medicine in chronic liver disease. Hepatology 2001; 34:595-604.
43. Vendemiale G, Grattagliano I, Portincasa P, Serviddio G, Palasciamo G, Altomare E: Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest 2001; 31:54-63.
44. Poli, G, Parola M: Oxidative damage and fibrinogenesis. Free Radic Biol Med 1997; 22:287-305.